Global Alcoholic Hepatitis Pipeline Review 2021: Drugs In Development - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Alcoholic Hepatitis (Gastrointestinal) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
The Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)
Key Topics Covered:
- Alcoholic Hepatitis - Overview
- Alcoholic Hepatitis - Therapeutics Assessment
- Alcoholic Hepatitis - Companies Involved in Therapeutics Development
- Alcoholic Hepatitis - Drug Profiles
- Alcoholic Hepatitis - Dormant Projects
- Alcoholic Hepatitis - Discontinued Products
- Alcoholic Hepatitis - Product Development Milestones
- Cadila Healthcare Ltd
- DURECT Corp
- Evive Biotech
- ImmuneMed Inc
- Intercept Pharmaceuticals Inc
- Novartis AG
- Pattern Therapeutics
- PharmaKing Co Ltd
- Rejuvenation Technologies Inc
- Surrozen Inc
- Vectus Biosystems Ltd
- Verlyx Pharma Inc
- Virpharm Pharmaceutical Co
For more information about this report visit https://www.researchandmarkets.com/r/c90xqx
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900